Erenumab and Possible CGRP Effect on Chronotype in Chronic Migraine: A Real-Life Study of 12 Months Treatment

The introduction of monoclonal antibodies (mAbs) directed against the calcitonin gene-related peptide (CGRP), or its receptor (CGRPr), revolutionized migraine management due to their high efficacy and few side effects. Data suggest that the CGRP may even be implicated in circadian rhythm, but studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Pilati, Laura, Torrente, Angelo, Di Marco, Salvatore, Ferlisi, Salvatore, Notaro, Giulia, Romano, Marika, Alonge, Paolo, Vassallo, Lavinia, Ferraù, Ludovica, Autunno, Massimo, Grugno, Rosario, Camarda, Cecilia, Brighina, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219555/
https://www.ncbi.nlm.nih.gov/pubmed/37240692
http://dx.doi.org/10.3390/jcm12103585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219555/
https://www.ncbi.nlm.nih.gov/pubmed/37240692
http://dx.doi.org/10.3390/jcm12103585

Ejemplares similares